Objective The aim of this study was to compare the therapeutic outcomes of high-intensity focused ultrasound (HIFU) and surgical treatment for abdominal wall endometriosis.
Introduction
Abdominal wall endometriosis (AWE) is defined as the finding of endometrial glands and stoma in abdominal wall. 1 It is the most common kind of extrapelvic endometriosis, usually responding to hormonal stimuli. 2 Most AWEs are associated with uterine surgical procedures such as caesarean section delivery, hysterectomy and amniocentesis; 3, 4 among these, caesarean section is the surgical procedure most frequently related to AWE, 5 with an incidence of approximately 0.03-0.47%. 6 Increasing pain and abdominal mass size in or near the previous surgical scar during menstruation were the most common presentation of AWE. 7 As the caesarean delivery rate has increased to 50% in China, the number of AWE patients has increased concomitantly. 8 AWE may also cause serious psychological burden and restrict daily activities. Therefore, effective treatment for AWE is important. Surgical resection, as a typical treatment, has been widely used to treat AWE. Previous studies have shown that surgical resection has a high success rate for the treatment of AWE. 9, 10 However, resection of the lesion is invasive and post-treatment pain is nearly universal, so some women with AWE *Xiaogang Zhu and Lixing Chen are joint first authors who contributed equally to this study. are unwilling to undergo surgical procedures. High-intensity focused ultrasound (HIFU) ablation, as a non-invasive treatment, has been widely applied in treating solid tumours for the past 10 years. [11] [12] [13] It has also been used as a non-invasive ablative therapy for uterine fibroid and adenomyosis. 14, 15 In 2009, Wang Yang et al. 4 used HIFU to treat 21 patients with AWE; their preliminary results revealed that HIFU appears to be safe and effective in the treatment of AWE. To our knowledge, no study has been performed comparing HIFU ablation with surgical resection in the management of AWE. Therefore, the purpose of this study was to compare the therapeutic efficacy and advantages of HIFU and surgical resection for the treatment of AWE.
Materials and methods
From April 2009 to March 2015, 51 patients with AWE were enrolled in our study. The inclusion criteria were as follows: (1) abdominal wall mass developing after previous uterine surgery; (2) gradually increasing mass with cyclic pain in or near the previous abdominal surgery scar that is exacerbated during menstruation (3) detectable hypoechoic nodule in the abdominal wall on ultrasound (4) the availability of complete clinical data.
Exclusion criteria were as follows: (1) inflammation or ulceration of the skin in or near the nodule (2) suspected or confirmed malignancy.
After the clinical diagnosis was made, two treatment options were offered to the patients. Twenty-three of 51 patients chose HIFU treatment and 28 patients chose treatment with surgical resection. All patients were treated during their non-menstrual period.
Ultrasound-guided HIFU ablation
Ultrasound-guided HIFU treatment was performed with a JC-200 focused ultrasound tumour therapeutic system (Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China). The therapeutic energy was produced by a 20-cm-diameter transducer with a focal length of 15 cm. An ultrasound imaging probe (My-Lab70, Esaote, Italy) is situated at the centre of the transducer and provides real time sonographic monitoring during HIFU treatment. The therapeutic transducer is located in a water tank filled with degassed water and its movement is controlled by a computer. The HIFU beam is directed upward, focusing on the AWE through the skin. 16 Before the HIFU procedure, all patients were requested to take bowel preparations for three days and to shave and degrease their anterior abdominal wall from the umbilicus to the level of the pubic symphysis. A urinary catheter was then inserted to control the bladder volume. HIFU ablation was performed under conscious sedation with fentanyl and midazolam via the peripheral vein. The patients were carefully positioned prone on the HIFU table with the abdominal skin in contact with the degassed water over the transducer in a sealed tank. The patient's blood pressure, pulse and respiration rate were monitored continuously, and the patients were requested to inform the doctor of any pain or discomfort during HIFU treatment. Real-time ultrasound was used to target the nodule by moving the integrated probe ( Figure 1A ). The AWE lesion was divided into sections with a thickness of 3 mm. An acoustic output power of 100-300 W was used. HIFU energy was intermittently applied, each energy exposure lasting for one-second, with a rest period of two-seconds. After ablation of the spot, the transducer was moved, and a nearby spot was treated similarly. This process was repeated section by section in successive sweeps from the deep to shallow regions until the entire nodule and a 1-cm margin around it was ablated. 4 HIFU sonication terminated when a grey-scale change at the treated spot was observed on colour Doppler ultrasound. Contrast-enhanced ultrasound (SonoVue, Bracco, Italy) was used to check the blood perfusion in the AWE lesion before and after the HIFU treatment (Figure 1B, C) . 
Surgical resection
The patients who underwent surgery were asked to fast for 6-8 hours before treatment. Surgery was performed under intraspinal anaesthesia in the operation theatre. Because of the infiltrative growth of AWE, excision must consist of removing any segments of skin, subcutaneous tissue, muscle and peritoneum at least 1 cm around the nodule to provide a safety margin. Polypropylene mesh is used to strengthen the abdominal wall; a defect in the abdominal wall is usually caused by wide excision of the AWE. 17 Finally, the surgery ended with a layer-by-layer suture of the abdominal wall with an aseptic dressing. All the patients in the surgery group were confirmed to have AWE by their pathology reports. Histological confirmation of endometriosis is based on finding two or three of the following endometrial characteristics: stroma, endometrial-like glands and hemosiderin pigment. 18 
Follow-up observation
Following the approved protocol, the hospital stay and the adverse effects were recorded. The cyclic pain score after treatment was evaluated by visual analogue scale (VAS) at 1, 3, 6 and 12 months, respectively. All patients were asked to return to our outpatient department for a colour Doppler ultrasound examination at 1, 3, 6 and 12 months to evaluate the change of the nodules.
Statistical methods SPSS 17.0 (SPSS, Inc.) was used for statistical analysis. All data shown are presented as mean AE standard deviation (SD) and range. The t-test and rank sum test were used for analysis of the data. P < 0.05 was considered statistically significant. Table 1 showed the average age of the patients was 30.1 AE 4.9 years (range: 23-40) in HIFU group and it was 31.4 AE 4.4 years (range: 24-39) in the surgery group. The average pain score before management was 5.1 AE 1.7 (range: 2-8) in HIFU group and 4.5 AE 1.6 (range: 2-8) in the surgery group. The average largest diameter of the nodule was 27.0 AE 13.4 mm (range: 13-68) in HIFU group and 26.8 AE 12.6 mm (range: 7-50) in the surgery group. The median time since caesarean delivery was 48 months (range: 16-132) in HIFU group and 48 months (range: 16-120) in the surgery group. The median interval time between caesarean delivery and the first symptoms was 24 months (range: 1-126), whereas in the surgery group it was 17 months (range: 2-96). The average number of caesarean deliveries was 1.1 AE 0.3 (range: 1-2) in the HIFU group and 1.0 AE 0.2 (range: 1-2) in the surgery group. No statistically significant difference between the two groups of patients was observed in age, the pain score before treatment, the largest diameter of the nodule, the time since caesarean delivery, the interval time between caesarean delivery and the first symptoms or the number of caesarean deliveries (P > 0.05).
Results

HIFU and surgery resection evaluation
In the HIFU group, one session of HIFU treatment was performed on every patient. The median treatment time was 60 minutes (range: 22-140). The median HIFU sonication time was 300 seconds (range: 100-858). The contrastenhanced ultrasound examination showed no perfusion in the AWE lesion immediately after the HIFU treatment ( Figure 1C ). In the HIFU group, no patient had skin burn, and there was neither blood loss nor a new scar. In contrast, in the surgery group every patient had a new scar after excision of the nodule with an average amount of blood loss of 20 ml (range: 5-200 ml). In the HIFU group, patients underwent treatment under conscious sedation without anaesthesia, whereas in the surgery group, surgery was carried out under lumbar or epidural anaesthesia. The average immediate pain score was 3.4 AE 1.2 in the HIFU group and 5.5 AE 1.5 in the surgery group. The median time for hospital stay was five days (range: 3-7) in the HIFU group and eight days (range: 4-10) in the surgery group. Statistically significant differences existed in length of hospital stay and the immediate pain score between the HIFU and surgery groups (P < 0.05) ( Table 2 ). The HIFU group had a shorter average hospital stay and lower average immediate pain score compared with the surgery group (P < 0.05).
Follow-up results
Both HIFU and surgery are effective in relieving cystic pain and shrinking AWE nodules, or even make them disappear. The treatment of every patient in this study was considered to be a success, as their pain was relieved from the upper level down to a lower level (1-3, slight pain; 4-6, moderate pain; 7-10, severe pain) and the nodules all decreased in size; some even disappeared. In the HIFU group the median pain scores after treatment at 1, 3, 6 and 12 months were 1 (range: 0-5), 1 (range: 0-3), 1 (range: 0-5), and 1 (range: 0-5), respectively. In the surgery group the median pain scores were 1 (range: 0-3), 1 (range: 0-4), 1 (range: 0-4), and 1 (range: 0-4), respectively. No statistical differences existed in pain relief between the two groups when compared during the same period (P > 0.05) (see Table 3 ). However, the size change in the nodules was clearly more noticeable in the surgery group than in the HIFU group (P ≤ 0.05) (see Table 3 ). In the surgery group the median largest diameters of a nodule on ultrasound after management at 1, 3, 6 and 12 months were 0 mm (range: 0-10), 0 mm (range: 0-12), 0 mm (range: 0-17) and 0 mm (range: 0-17), respectively, whereas in the HIFU group they were 15 mm (range: 10-26), 15 mm (range: 8-25), 14 mm (range: 7-24) and 12 mm (range: 6-25), respectively.
Discussion
HIFU is a non-invasive technique that focuses extracorporeal low intensity ultrasound on the target lesion to form a focal point of high intensity ultrasound that causes instant coagulative necrosis of the tissue without any noticeable damage to adjacent tissues. By controlling the three-dimensional aggregate motion of the focal point, conformal ablation therapy for the targeted lesion can be performed.
The treatment goal for AWE is not only to relieve the abdominal cyclic pain and shrink the lesion, but also to carry out a minimally invasive treatment for the patients. HIFU, as a non-invasive therapy, has been used in the management of AWE, 19 as HIFU ablation not only destroys the AWE lesion but also causes the ectopic endometrium lose its function. 20 One previous study focused on the efficiency of HIFU, has revealed that HIFU is safe and effective for the treatment of AWE. 4 That study had its limitations due to the lack of comparison with other traditional treatments. In this present study, the results showed no statistically significant differences in pain relief during the followup period (range: 1-12 months) between the patients treated by HIFU and those treated by surgical resection. However, in the surgery group the largest diameter of the AWE lesion on ultrasound after treatment was significantly smaller than in the HIFU group. This is because in the HIFU group, the AWE lesion was only destroyed, whereas in the surgery group, the lesion was removed. Therefore, the results demonstrated that HIFU is as effective as surgery resection for the pain relief of AWE in the short-term.
Besides the efficiency of HIFU ablation, the safety of the treatment for AWE is another main concern. In this study, we found that both HIFU and surgical resection are safe for the treatment of AWE. During and immediately after treatment in all patients the most common adverse effect was pain in the treated region. In the HIFU group the patients suffered significantly milder pain with a lower pain score compared with the surgery group. From the previous studies, the complications of HIFU ablation included skin burn along the acoustic path, which is manifested by blistering or induration. 15 Besides this, intestinal injury is also a potential complication. 19 In this study, skin burn or intestinal injury was not reported in our patients. HIFU treatment, leaving no new scar and entailing no blood loss, can preserve the integrity of the skin under conscious sedation, whereas surgical resection creates a new scar above the previous one, and is carried out under lumbar or epidural anaesthesia with an average blood loss of 20 ml. In addition, the hospital stay in the HIFU group was obviously shorter than that of surgery group. All of these results revealed that both HIFU and surgery are safe for the treatment of AWE. However, compared with surgical resection, HIFU treatment has the advantages of being non-invasive and requiring shorter recovery time. However, during the follow-up time, there was recurrence of the AWE in one patient after HIFU treatment a year later, ultimately requiring a wide surgical excision. We have reviewed this case carefully and found that she had had surgical resection for AWE twice before, and each time, cyclic pain recurred within half a year. The lesion was very deep and close to the parietal peritoneum. To avoid intestinal injury, lower energy exposure was used and the AWE lesion close to the parietal peritoneum could not be totally destroyed. This is a reminder to avoid choosing HIFU ablation to treat patients with a deep lesion close to the parietal peritoneum.
In our study, the AWE nodule of seven patients in HIFU group disappeared entirely and the rest shrank. After HIFU ablation, the ablated lesion had no biological activity; its surrounding blood supply was destroyed at the same time as it was, leaving what was left of the necrotic lesion to shrink slowly. Pain relief is the main concern of the patients and the technique success was defined as pain relief. It is necessary to inform patients of the possible continued existence of the nodule after management of pain before drawing up the treatment plan.
This study is limited because it is a retrospective observational study. Although the main demographic characteristics showed no differences in the two groups, some other unexpected factors may exist and affect the results. Another limitation of this study is the small number of subjects. Finally, the follow-up time was short. In the future, prospective, randomized, and multi-centre studies with a large number of patients and longer follow-up time are needed.
Conclusion
Based on our results with small number of patients and short follow-up time, it appears that both HIFU and surgical resection are safe and effective in treating patients with AWE. Compared with surgery, HIFU treatment for AWE has the advantages of a shorter hospital stay, no blood loss, no new scar, no anaesthesia and a lower immediate pain score. It would be a promising alternative treatment for patients with AWE.
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